What Does The Data Behind Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Suggest?


Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) closed its last session at $2.15. The stock traded within a range of $2.10 and $2.80. The company operates in the Healthcare sector with a market capitalization of 112250. Trading volume for Tetraphase Pharmaceuticals, Inc. was 16.81 Million in its previous trading session. Currently, Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has an average volume of 494.98 Million.

Company Profile

Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts.

Analyst Views

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) received a Buy rating from 1 analysts. 0 analysts gave its stock an Outperform rating. 1 analysts say it’s a Hold while 0 analysts provided their expert opinion as Sell.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) touched its 1-Year High price of $9.93 on 03/31/17 and its 1-Year Low price of $2.10 on 02/14/18.

EPS & Financials

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) reported its EPS in the last quarter as $-0.63/Share beating the analyst estimate of $-0.69/Share by a difference of $0.06. This showed a surprise of 8.7% in the last quarter earnings.

For the current quarter, 6 analysts are projecting a mean EPS of $-0.64/share. According to their observations and findings, the stock could provide a high EPS of $-0.58/share and a low EPS of $-0.69/share.

Analysts believe that the company has the potential to earn average revenue of $2.41 Million for the current quarter. According to their predictions high & low revenue estimates are 4.3 Million and 1.5 Million respectively.

Technical Analysis

By taking a look at the stock’s current statistics it can gauged that the stock candle is BEARISH with HIGH volatility. Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has a 20-Day average volume of 1.27 Million. According to today’s trading volume Tetraphase Pharmaceuticals, Inc. is ABOVE its 20-Day Avg. volume with the stock showing ABOVE Abnormal volume in the past 150 days.

Moving average convergence divergence (MACD) shows that the stock is on a PRICE RELATIVITY trend. The trend for the past 10-days shows that the company was in BEARISH territory while an analysis of the last 40-Day trend shows a BEARISH signal. The 100-Day trend also shows a BEARISH trend as well.

The company currently has an insider ownership of 0.4 Percent and Institutional ownership of 63.7 Percent. The return on assets stands at -77.5%, Return on Equity currently is -88.3% and the Return on Investment value is -55.6%.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) gross margin percentage stands at 0% while its operating margin for the past trailing twelve month is 0 percent and its overall profit margin (ttm) is 0 Percent. The stock is currently moving below its 20-Day Simple Moving Average of -63.36% with a 50-Day Simple Moving Average of -64.55 percent. As of today, the company has a SMA200 (200-day simple moving average) of -67.83 Percent. The Stock has YTD (year to date) performance of -65.87 percent.

The TTM operating margin for the company stands at 0%. The return on invested capital is at -55.6%, which is good, compared to its peers. The Free Cash Flow or FCF margin is 0.

The company’s stock is currently moving with a -ve distance from the 200 day SMA of approximately -67.83%, and has a solid year to date (YTD) performance of -65.87% which means that the stock is constantly adding to its value from the previous fiscal year end price.